See more : Hudson Global, Inc. (HSON) Income Statement Analysis – Financial Results
Complete financial analysis of Rekah Pharmaceutical Industry Ltd. (REKA.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rekah Pharmaceutical Industry Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Vartech Systems Inc. (VRTK) Income Statement Analysis – Financial Results
- Generation Alpha, Inc. (GNAL) Income Statement Analysis – Financial Results
- CanSino Biologics Inc. (CASBF) Income Statement Analysis – Financial Results
- Asia Biomass Public Company Limited (ABM.BK) Income Statement Analysis – Financial Results
- The People’s Insurance Company (Group) of China Limited (1339.HK) Income Statement Analysis – Financial Results
Rekah Pharmaceutical Industry Ltd. (REKA.TA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rekah.co.il
About Rekah Pharmaceutical Industry Ltd.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.66M | 292.39M | 263.95M | 265.47M | 196.50M | 207.83M | 208.18M | 218.39M | 262.43M | 216.37M | 270.03M | 270.00M |
| Cost of Revenue | 241.46M | 213.69M | 198.79M | 196.83M | 135.38M | 141.09M | 140.08M | 150.62M | 181.13M | 151.01M | 183.42M | 184.67M |
| Gross Profit | 80.20M | 78.71M | 65.16M | 68.64M | 61.12M | 66.74M | 68.10M | 67.76M | 81.30M | 65.36M | 86.61M | 85.33M |
| Gross Profit Ratio | 24.93% | 26.92% | 24.69% | 25.86% | 31.10% | 32.11% | 32.71% | 31.03% | 30.98% | 30.21% | 32.07% | 31.60% |
| Research & Development | 3.78M | 3.23M | 2.08M | 1.54M | 1.71M | 2.59M | 2.45M | 1.93M | 1.38M | 1.50M | 0.00 | 0.00 |
| General & Administrative | 30.69M | 8.54M | 6.41M | 5.94M | 5.67M | 6.32M | 6.68M | 5.74M | 5.15M | 5.61M | 6.15M | 18.01M |
| Selling & Marketing | 40.35M | 4.08M | 3.64M | 2.31M | 3.15M | 3.85M | 5.34M | 8.16M | 9.35M | 8.97M | 11.96M | 44.71M |
| SG&A | 71.04M | 12.62M | 10.05M | 8.25M | 8.83M | 10.17M | 12.01M | 13.91M | 14.50M | 14.58M | 18.11M | 72.29M |
| Other Expenses | 0.00 | 47.69M | 39.34M | 37.03M | 37.91M | 39.60M | 40.68M | 43.76M | 64.00K | 150.00K | 61.75M | 0.00 |
| Operating Expenses | 79.67M | 63.54M | 51.47M | 46.82M | 48.45M | 52.36M | 55.15M | 59.60M | 75.27M | 60.93M | 79.86M | 71.76M |
| Cost & Expenses | 321.13M | 277.23M | 250.26M | 243.65M | 183.83M | 193.45M | 195.23M | 210.22M | 256.40M | 211.94M | 263.28M | 256.43M |
| Interest Income | 7.58M | 42.00K | 66.00K | 187.00K | 87.00K | 187.00K | 161.00K | 376.00K | 574.00K | 218.00K | 210.00K | 7.98M |
| Interest Expense | 0.00 | 5.65M | 5.63M | 5.81M | 5.10M | 4.31M | 4.76M | 5.56M | 6.27M | 7.22M | 7.01M | 0.00 |
| Depreciation & Amortization | 23.12M | 27.48M | 22.86M | 19.71M | 16.90M | 10.75M | 10.16M | 9.75M | 8.87M | 8.19M | 6.83M | 6.49M |
| EBITDA | 26.03M | 40.24M | 36.20M | 39.68M | 26.55M | 26.42M | 22.95M | 17.71M | 14.36M | 13.64M | 25.29M | 19.53M |
| EBITDA Ratio | 8.09% | 13.76% | 13.79% | 15.07% | 13.79% | 12.09% | 11.02% | 8.11% | 5.47% | 6.30% | 5.17% | 7.23% |
| Operating Income | 2.91M | 13.25M | 14.15M | 20.92M | 11.53M | 14.22M | 11.60M | 7.46M | 1.12M | 5.30M | 18.12M | 13.04M |
| Operating Income Ratio | 0.90% | 4.53% | 5.36% | 7.88% | 5.87% | 6.84% | 5.57% | 3.42% | 0.43% | 2.45% | 6.71% | 4.83% |
| Total Other Income/Expenses | -9.96M | -12.90M | -5.20M | -6.77M | -6.99M | -4.65M | -31.70M | -17.37M | -3.94M | -5.70M | -6.67M | -7.45M |
| Income Before Tax | -7.05M | 357.00K | 7.71M | 14.16M | 4.54M | 9.92M | -20.16M | -9.90M | -3.64M | -595.00K | 11.46M | 5.59M |
| Income Before Tax Ratio | -2.19% | 0.12% | 2.92% | 5.33% | 2.31% | 4.77% | -9.68% | -4.54% | -1.39% | -0.27% | 4.24% | 2.07% |
| Income Tax Expense | 138.00K | 2.40M | 1.10M | 3.36M | 1.79M | 3.07M | 2.44M | 1.10M | 715.00K | -154.00K | 3.07M | 1.81M |
| Net Income | -6.91M | -2.04M | 6.62M | 10.80M | 2.76M | 7.03M | -22.48M | -11.00M | -4.41M | -501.00K | 8.32M | 7.40M |
| Net Income Ratio | -2.15% | -0.70% | 2.51% | 4.07% | 1.40% | 3.38% | -10.80% | -5.04% | -1.68% | -0.23% | 3.08% | 2.74% |
| EPS | -0.61 | -0.18 | 0.58 | 0.95 | 0.24 | 0.64 | -2.34 | -1.15 | -0.53 | -0.09 | 1.52 | 1.35 |
| EPS Diluted | -0.61 | -0.18 | 0.58 | 0.95 | 0.24 | 0.64 | -2.34 | -1.15 | -0.53 | -0.09 | 1.52 | 1.35 |
| Weighted Avg Shares Out | 11.33M | 11.34M | 11.41M | 11.41M | 11.41M | 10.92M | 9.60M | 9.57M | 8.39M | 5.46M | 5.46M | 5.46M |
| Weighted Avg Shares Out (Dil) | 11.41M | 11.41M | 11.41M | 11.41M | 11.41M | 10.92M | 9.60M | 9.60M | 8.39M | 5.46M | 5.46M | 5.46M |
Source: https://incomestatements.info
Category: Stock Reports